Antimicrobial peptides in oral medicine: Unlocking new possibilities for treatment
KNOXVILLE, TN, December 12, 2025
Antimicrobial peptides (AMPs) are nature's powerful tools, offering a wide range of benefits in oral medicine. These small-molecule polypeptides are the body's innate immune system's secret weapon, capable of fighting off harmful bacteria while promoting healing and tissue regeneration. Unlike traditional antibiotics, AMPs work by physically destroying bacterial cell membranes, a unique mechanism that significantly reduces the risk of bacterial resistance.
In a recent study published in Translational Dental Research, a team of Chinese researchers delved into the world of AMPs, exploring their classification, antimicrobial mechanisms, and therapeutic applications in various oral diseases. The findings are impressive, to say the least.
"AMPs like Temporin-GHa derivatives, ZXR-2, and GH12 are highly effective in treating dental caries," explains senior author Qiang Feng. "They inhibit the growth of cariogenic bacteria, disrupt biofilm formation, and even promote tooth remineralization. For periodontitis, human-derived AMPs such as α-defensins and β-defensins, along with synthetic peptides like Nal-P-113, effectively target periodontal pathogens, regulate inflammatory responses, and enhance tissue regeneration."
In oral cancer therapy, AMPs such as Piscidin-1 and LL-37 play a dual role. They induce cancer cell death through membrane disruption and apoptotic pathways while also modulating anti-tumor immune responses. Additionally, AMPs like P-113 and Nisin A have shown remarkable efficacy in treating oral candidiasis, while peptides such as IB-367 and Histatin-5 alleviate oral mucositis by inhibiting infection and promoting wound healing.
The clinical potential of AMPs is further highlighted by several ongoing clinical trials. C16G2 is being tested for dental caries, Nal-P-113 for periodontitis, and P-113 for oral candidiasis. Beyond direct therapy, AMPs are being developed into implant coatings to prevent peri-implant infections, oral dressings for sustained release, and combined with antibiotics or nanoparticles to enhance therapeutic effects. They also show promise as diagnostic markers for oral diseases by detecting changes in their expression levels.
However, the clinical translation of AMPs is not without challenges. Oral enzymes, pH fluctuations, and high salt concentrations can affect their stability. Cationic and amphiphilic properties may lead to cytotoxicity and immunogenicity, while large-scale production can be costly. To address these issues, researchers have developed innovative strategies, including chemical modification, nanocarrier delivery systems, sequence optimization with D-amino acids, and microbial/plant-based heterologous expression.
"These strategies aim to improve stability, reduce toxicity, and lower production costs," says Feng. "AMPs' multifunctional properties and low resistance potential make them a game-changer in oral medicine."
The authors emphasize the need for future research to focus on clarifying AMPs' interaction mechanisms with oral microbiota and host cells, accelerating peptide screening through artificial intelligence, and developing tailored formulations for the oral microenvironment to promote clinical application.
This groundbreaking research not only highlights the potential of AMPs in oral medicine but also opens up exciting possibilities for the future of dental care.
